Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS).

Published in:

British Journal of Dermatology, 2020, v. 183, n. 2, p. 265, doi. 10.1111/bjd.18696

By:

• Thaçi, D.;
• Pinter, A.;
• Sebastian, M.;
• Termeer, C.;
• Sticherling, M.;
• Gerdes, S.;
• Wegner, S.;
• Krampe, S.;
• Bartz, H.;
• Rausch, C.;
• Mensch, A.;
• Eyerich, K.

Publication type:

Article